Breast Lift in Cyprus
Breast Lift in Cyprus section, includes general infrmation about Breast Lift Procedure, Breast Lift Cyprus Local News, Breast Lift Cyprus Surgeon Locator and other Breast Lift related material.
Breast Lift Procedure
A mastopexy or breast lift is a surgical procedure performed to reshape the breast and return it to a more youthful position. Drooping of the breast may occur after pregnancy as well as aging. Frequently a breast implant may be used in conjunction with a breast lift in order to achieve better results. Depending on the amount of breast lifting that needs to be accomplished, different techniques may be used that involve different incisions. Generally, the more lifting that is required, the larger the incision (and therefore the scar).
Other Breast Lift Procedures
All Breast Procedures
Breast Lift Cyprus (current)
Cyprus Breast Reduction
Cyprus Breast Implants
Cyprus Implant Removal
Cyprus Armpit Incision
More Cyprus info...
Cyprus By bus As of July 2005 Cyprus' on-again, off-again intercity bus services appear to be running again. Enquire locally. It will cost CYP 0.80 for few KM ride and frequency is 30M to 1 Hr in limassol city.
Cyprus By plane Cyprus' main airport is Larnaca International Airport (LCA) and is located on the outskirts of Larnaka.
The previous main international airport located SW of Nicosia is now located on the Green Line separating the Greek and Turkish parts of Cyprus - it has been out of use since 1974.
Cyprus is serviced by a variety of different carriers, the main one being the Cypriot Cyprus Airways. There are flight connections with most major European towns, e.g. London, Birmingham, Manchester, Frankfurt, Paris, Amsterdam, Rome, Milan) and many Eastern European countries. Unfortunately almost all non-Cyprus Airways scheduled flights arrive and depart in the middle of the night (2/3 o'clock). There are also connections to almost all Middle Eastern capitals. There are no flights to Turkey from the south.
There are also charter flights to the western airport of Paphos.
Plastic Surgery News...
- According to the results of a pilot trial published early online in the Lancet Neurology, early intensive lowering of blood pressure after acute intracerebral haemorrhage (ICH) is clinically feasible and warrants further investigation in a large, randomised trial.
This study was conducted as a run in to a larger clinical trial, and involved over 400 patients with acute ICH who had elevated systolic blood pressure (150-200mmHg). All had been diagnosed by CT within six hours of symptom onset, and had no known definite indications or contra-indications to treatment. They were randomised to intensive lowering of blood pressure to a target systolic of 140mmHg (n=203) or to standard management (target systolic 180mmHg; n=201). The primary efficacy endpoint was the proportional change in haematoma volume at 24 hours.
The main findings were as follows:
• At 24 hours, the mean proportional haematoma growth was 36.3% in the guideline group and 13.7% in the intensive group (difference 22.6%, 95% CI 0.6–44.5%; p=0.04). After adjustment for initial haematoma volume and time from onset to CT, the inter-group difference was no longer statistically significant (p=0.06)
• The absolute difference in haematoma volume was 1.7mL (95% CI -0.5 to 3.9; p=0.13).
• From randomisation to 1 h, mean systolic BP was 153 mmHg in the intensive group and 167 mmHg in the standard group (inter-group difference of 13.3 mmHg, 95% CI 8.9–17.6 mmHg; p<0.0001)
• Between 1 and 24 hours, the mean systolic BP was 146 mmHg in the intensive group and 157 mmHg in the guideline group (inter-group difference of 10.8 mmHg, 95% CI 7.7–13.9 mmHg; p<0.0001).
The authors conclude that a large randomised trial is needed to define the effects of early intensive BP-lowering treatment on clinical outcomes across a broad range of patients with ICH.
[Editor’s note: this summary was taken from the abstract, which did not contain any details of the drug regimens used.]
- Heart disease is a major complication of lupus and is now a leading cause of death among people living with autoimmune disease. Individuals with lupus are at increased risk for cardiovascular disease (CVD), which involves hardening of the arteries and can lead to heart attacks or strokes later in life.